On the other hand, avapritinib has shown durable clinical efficacy in the treatment of gastrointestinal stromal tumors (GIST) with activating mutations in KIT and PDGFRα, which were previously considered untreatable due to resistance to TKI35. This evidence concerns the gene KIT and gastrointestinal stromal tumor.